Malignant melanoma is one of the most dangerous forms of cancer. Around half of melanomas and about 7% of all other cancers ...
Company requested Type B pre-IND meeting with U.S. FDA to discuss development and regulatory strategy for its investigational tetravalent T-cell engager, HCW11-018b ...
Scientists are getting closer to understanding the wasting and fatigue that often accompanies cancer. Treatments could be on ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug ...
In an interview, Carl H. June discusses how CAR-T therapy transformed blood cancer treatment, the challenges of extending it ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (the 'Company'; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of ...
Saturn goes retrograde on July 26, marking the beginning of a period of reflection, discipline, and inner transformation.
Cyclists are being given a unique opportunity to explore North Leitrim’s hidden gems when the annual Leitrim Glens Sportive ...
Researchers are applying evolutionary theory to cancer by changing treatments before tumors have time to develop resistance. Mathematical models suggest that rapid, carefully timed switches between ...
Several types of cancer are triggered by mutations in a protein called BRAF. Researchers at the Paul Scherrer Institute PSI ...
Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.
Automated, detergent-free purification preserves native membrane protein structure while supporting more reliable target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results